RT Journal Article SR Electronic T1 The therapeutic effectiveness of Convalescent plasma therapy on treating COVID-19 patients residing in respiratory care units in Baghdad, Iraq JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.06.24.20121905 DO 10.1101/2020.06.24.20121905 A1 Rasheed, Anwar M. A1 Fatak, Dhurgham F A1 Hashim, Hashim A. A1 Maulood, Mohammed F A1 Kabah, Khulood K A1 Almusawi, Yaqoob A. A1 Abdulamir, Ahmed S YR 2020 UL http://medrxiv.org/content/early/2020/06/30/2020.06.24.20121905.abstract AB Objectives The current COVID-19 pandemic needs unconventional therapies to tackle the resulted high morbidity and mortality. Convalescent plasma is one of the therapeutic approaches that might be of benefit.Methods Forty nine early-stage critically-ill COVID-19 patients residing in RCU of three hospitals in Baghdad, Iraq were included, 21 received convalescent plasma while 28 did not receive, namely control group. Recovery or death, length of stay in hospital, and improvement in the clinical course of the disease were monitored clinically along with laboratory monitoring through SARS-CoV-2 RNA detection via PCR, and SARS-CoV-2 IgG and IgM serological monitoring.Results Patients received convalescent plasma showed reduced duration of infection in about 4 days, and showed less death rate, 1/21 versus 8/28 in control group. In, addition, all of the patients received convalescent plasma showed high levels of SARS-CoV-2 IgG and IgM 3 days after plasma transfusion. Plasma from donors with high levels of SARS-CoV-2 IgG and donors with positive SRAS-CoV-2 IgM showed better therapeutic results than other donors.Conclusions Convalescent plasma therapy is an effective mode of therapy if donors with high level of SARS-Cov2 antibodies are selected and if recipients were at their early stage of critical illness, being no more than 3 days in RCU.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThe study is registered in ClinialTrials.gov Registration number: NCT04441424 The registration of the clinical trial is retrospective because there was an administrative delay, amid the pandemic turmoil, to consent to register this Iraqi clinical trial in international data base.Funding StatementThe study was funded by the Baghdad-Alkarkh general Directorate of HealthAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the IRB of the Baghdad-Alkarkh general Directorate of HealthAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data are available